

Applicants: Ulrich Laemmli and Samuel Janssen  
U.S. Serial No.: Not Yet Known  
(Continuation-In-Part of U.S. Serial No. 09/614,036,  
filed July 11, 2000)  
Filed: Herewith  
Page 4

REMARKS


By this Preliminary Amendment, applicants have hereinabove amended the specification to include a reference to a parent application and amended the claims merely to reduce the filing fee. Accordingly, upon entry of this Amendment, claims 1-5, 51-57, 69, 70-72, 79 and 80-82 are pending in this application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

Applicants: Ulrich Laemmli and Samuel Janssen  
U.S. Serial No.: Not Yet Known  
(Continuation-In-Part of U.S. Serial No. 09/614,036,  
filed July 11, 2000)  
Filed: Herewith  
Page 5

No fee other than the filing fee of \$ 355.00 is deemed necessary  
in connection with this Preliminary Amendment. However, if any  
other fee is required, authorization is hereby given to charge  
the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Reg. No. 28,678  
Gary J. Gershik  
Reg. No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

U.S. Patent and Trademark Office

Applicants: Ulrich Laemmli and Samuel Janssen  
U.S. Serial No.: Not Yet Known  
(Continuation-In-Part of U.S. Serial No. 09/614,036,  
filed July 11, 2000)  
Filed: Herewith  
Page 6

**Attachment A**  
**Amended claims with annotations of changes**

- 4. (Amended) DNA-binding molecule according to claim 2 ~~or 3~~ wherein said heterocyclic residue is chosen from pyrrole, imidazole, triazole, pyrazole, furan, thiazole, thiophene, oxazole, pyridine, or derivatives of any of these compounds wherein one or more of the heteroatoms are substituted by a substituent which is DNA-binding or non-DNA-binding.--  
-
- 51. (Amended) Process for binding double-stranded DNA in a sequence-specific manner, comprising contacting a DNA-target sequence within said DNA with a DNA-binding molecule according to ~~any one of claims 1 to 50~~, in conditions allowing said binding to occur.--
- 69. (Amended) Process for modulating chromosome function in a eukaryotic cell, comprising the step of contacting a genomic DNA element, comprising a binding site mediating chromosome function, with a molecule according to ~~any one of claims 1 to 50~~ and having the capacity to bind in a sequence-specific manner to said element, said step of contacting being carried out in conditions permitting binding of said compound to said element, wherein the binding modulates chromosome function.--

Applicants: Ulrich Laemmli and Samuel Janssen  
U.S. Serial No.: Not Yet Known  
(Continuation-In-Part of U.S. Serial No. 09/614,036,  
filed July 11, 2000)  
Filed: Herewith  
Page 7

- 70. (Amended) Process for modulating the function of a DNA element in a eukaryotic cell, Comprising the step of contacting a genomic DNA element, so-called "chromatin responsive element" (CRE), with a molecule according to ~~any one of~~ claims 1 ~~to~~ 50 and having the capacity to bind in a sequence-specific manner to said CRE, said step of contacting being carried out in conditions permitting chromatin remodeling of the CRE by said compound, wherein said chromatin remodeling of the CRE alters the activity of one or more other DNA elements, so called "modulated DNA elements" in the genome.--
- 79. (Amended) Pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1 ~~to~~ 50 in association with a physiologically acceptable excipient.--
- 80. (Amended) Compound according to ~~any one of~~ claims 1 ~~to~~ 50, for use in therapy.--
- 81. (Amended) Compound according to ~~any one of~~ claims 1 ~~to~~ 50 which is fluorescent or fluorescently labelled.--